Keymed Biosciences Announces Critical Milestone in Collaboration with AstraZeneca on Core Product CMG901 (AZD0901)

Key Highlights for Investors

• Multi-center, Phase III clinical trial initiated by AstraZeneca for CMG901 (AZD0901) in combination therapy for advanced/metastatic gastric cancers.
• Trigger of a US\$45 million milestone payment to Keymed Biosciences following first patient dosing in the pivotal study.
• CMG901 recognized as a first-in-class Claudin 18.2-targeting ADC with multiple regulatory designations, including Breakthrough Therapy in China and Orphan Drug/Fast Track in the US.
• Multiple global clinical trials underway for CMG901 addressing significant cancer indications beyond gastric cancer, such as pancreatic and biliary tract cancers.

Detailed Report

Keymed Biosciences Inc. announced a significant step forward in its collaboration with global pharmaceutical leader AstraZeneca AB on its core product, CMG901 (also known as sonesitatug vedotin or AZD0901). The announcement confirms that AstraZeneca has commenced a multi-center, randomized, controlled Phase III clinical trial (CLARITY-Gastric 02) evaluating CMG901 in combination with capecitabine, with or without rilvegostomig, as a first-line treatment for Claudin 18.2-positive and HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. The first patient has already received their initial dose.

This milestone is highly significant for investors as it triggers a milestone payment of US\$45 million from AstraZeneca to KYM Biosciences (a Keymed subsidiary 70% owned by Keymed and 30% by Innocube Limited under Lepu Biopharma). Keymed has confirmed receipt of this payment, net of bank charges, under the global exclusive out-license agreement signed with AstraZeneca in February 2023.

About CMG901 (AZD0901)

CMG901 is a Claudin 18.2-targeting antibody drug conjugate (ADC) that consists of a highly specific antibody, a cleavable linker, and a potent cytotoxic payload (monomethyl auristatin E, MMAE). It is distinguished as the first Claudin 18.2 ADC to receive IND approval in both China and the US.

Claudin 18.2 is a protein highly and selectively expressed in a range of solid tumors including gastric and pancreatic cancers, making it an attractive target for innovative cancer therapies. CMG901 has been recognized with several regulatory designations:

• Breakthrough Therapy Designation by China’s CDE for advanced gastric cancer resistant or intolerant to prior therapies (September 2022).
• Orphan Drug Designation and Fast Track Designation by the US FDA for relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma.

Clinical Development Pipeline

In addition to the pivotal Phase III trial, AstraZeneca is conducting several other important clinical studies involving CMG901, including:

• Phase III Study (CLARITY-Gastric 01): Comparing AZD0901 monotherapy against investigator-choice regimens in adults with advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma who have failed second or later-line treatments.
• Phase II Study (GEMINI-PeriOp GC): Evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD0901 or combination therapies as perioperative treatment for locally advanced, resectable gastroesophageal junction adenocarcinoma.
• Phase II Study (CLARITY-PanTumour01): Assessing safety, efficacy, and immunogenicity of AZD0901 as monotherapy or in combination for Claudin 18.2-expressing advanced solid tumors, including gastric, pancreatic, and biliary tract cancers.

The breadth of these trials highlights the potential for CMG901 to address multiple, high-need cancer indications on a global scale, which may significantly expand the company’s commercial opportunities.

Corporate Structure & Financial Implications

KYM Biosciences, the entity leading development of CMG901, is 70% owned by Keymed Biosciences and 30% by Innocube Limited (under Lepu Biopharma). The successful milestone payment and ongoing clinical progress reinforce Keymed’s leading position in ADC development and its partnership strategy with major pharmaceutical players.

Shareholder Considerations and Potential Impact on Share Price

• US\$45 million milestone payment is a material non-recurring income event, directly impacting Keymed’s cash position and validating the commercial value of CMG901.
• Advancement to Phase III clinical trials for a first-in-class ADC in major global indications is a significant de-risking event, likely to improve investor sentiment and valuation multiples.
• Ongoing clinical trials in multiple indications suggest a robust pipeline and potential for future milestone/royalty payments if development and approval milestones are met.
• Regulatory designations (Breakthrough, Orphan Drug, Fast Track) could facilitate expedited development, review, and potential market entry, positively affecting future revenue prospects.
• Shareholders should be aware of the risk warnings: There is no guarantee that CMG901 will ultimately achieve regulatory approval or commercial success. Caution is advised when trading shares.

Conclusion

The combination of a major milestone payment, a pivotal clinical trial launch by AstraZeneca, and multiple late-stage global studies positions Keymed Biosciences as a key player in the next generation of targeted cancer therapies. This announcement contains several events that are likely to be price sensitive and could significantly influence investor sentiment and the company’s market valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The development of pharmaceutical products is subject to significant scientific, regulatory, and commercial risks. Investors should exercise caution and consult their own financial advisors before making investment decisions.

View KEYMED BIO-B Historical chart here